SeaStar Medical Holding Corp 8-K, filed Mar 8, 2024
SeaStar Medical Holding Corp (ICU)
8-K
2024-03-08
For: 2024-03-06
View Original
Added on
April 09, 2026
About this 8-K
SeaStar Medical Holding Corp filed this 8-K on March 8, 2024, reporting on events of March 6, 2024.
Items reported
- Item 8.01: Other events
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 6, 2024
_________________
(Exact name of registrant as specified in its charter)
_____________________
|
|
|
|
|
|
|
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
|
|
|
|
|
(Address of principal executive offices)
|
|
(Zip code)
|
Registrant's telephone number, including area code (844 ) 427-8100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange
on which registered
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act
of 1934 (§240.12b-2 of this chapter):
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On March 6, 2024, SeaStar Medical Holding Corporation (the “Company”) received a letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock
Market, LLC (“Nasdaq”) granting the Company a temporary exception until June 24, 2024, subject to certain milestones, to regain compliance with the
Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”) by evidencing a closing bid price of $1.00 or more per
share for a minimum of ten consecutive trading sessions.
As previously reported, the Company received deficiency letters from the Staff of Nasdaq notifying the Company that for 30 consecutive
business days preceding June 26, 2023, the closing bid price of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) was
below $1.00 per share, which did not meet the requirement for continued listing on the Nasdaq Capital Market under the Minimum Bid Price Rule, and has since not regained compliance with the Minimum Bid Price Rule.
In response to such deficiency letters, the Company timely submitted a hearing request before the Nasdaq Hearings Panel, and also provided the
Nasdaq Hearings Panel with a plan to regain compliance, which plan included conducting a reverse stock split of the Company’s Common Stock if necessary, no later than June 7, 2024, to regain compliance with the Minimum Bid Price Rule.
The Company intends to monitor the closing bid price of its Common Stock and consider available options if its Common Stock does not trade at
a level likely to result in the Company’s regaining compliance with the Minimum Bid Price Rule by June 24, 2024. There can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Rule or that the Company will
otherwise be or remain in compliance with the other applicable Nasdaq listing standards.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
SeaStar Medical Holding Corporation
|
|||
|
By:
|
/s/ Eric Schlorff
|
||
|
Date:
|
March 8, 2024
|
Name:
|
Eric Schlorff
|
|
Title:
|
Chief Executive Officer
|